HRP20211676T1 - Novi biomarkeri za procjenu rizika neuspjeha alografta i smrtnosti pacijenata nakon transplantacije organa - Google Patents
Novi biomarkeri za procjenu rizika neuspjeha alografta i smrtnosti pacijenata nakon transplantacije organa Download PDFInfo
- Publication number
- HRP20211676T1 HRP20211676T1 HRP20211676TT HRP20211676T HRP20211676T1 HR P20211676 T1 HRP20211676 T1 HR P20211676T1 HR P20211676T T HRP20211676T T HR P20211676TT HR P20211676 T HRP20211676 T HR P20211676T HR P20211676 T1 HRP20211676 T1 HR P20211676T1
- Authority
- HR
- Croatia
- Prior art keywords
- gla
- proteins
- risk
- ucmgp
- patient
- Prior art date
Links
- 210000000056 organ Anatomy 0.000 title claims 3
- 238000002054 transplantation Methods 0.000 title claims 3
- 239000000090 biomarker Substances 0.000 title 1
- 238000000034 method Methods 0.000 claims 8
- 102100039809 Matrix Gla protein Human genes 0.000 claims 5
- 230000021523 carboxylation Effects 0.000 claims 4
- 238000006473 carboxylation reaction Methods 0.000 claims 4
- 229930003448 Vitamin K Natural products 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims 2
- 235000019168 vitamin K Nutrition 0.000 claims 2
- 239000011712 vitamin K Substances 0.000 claims 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims 2
- 235000020800 vitamin K status Nutrition 0.000 claims 2
- 229940046010 vitamin k Drugs 0.000 claims 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 claims 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 claims 1
- 101150022345 GAS6 gene Proteins 0.000 claims 1
- 102100025614 Galectin-related protein Human genes 0.000 claims 1
- 108090001053 Gastrin releasing peptide Proteins 0.000 claims 1
- 102000004067 Osteocalcin Human genes 0.000 claims 1
- 108090000573 Osteocalcin Proteins 0.000 claims 1
- 102100037765 Periostin Human genes 0.000 claims 1
- 101710199268 Periostin Proteins 0.000 claims 1
- 108010094028 Prothrombin Proteins 0.000 claims 1
- 102100027378 Prothrombin Human genes 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003114 blood coagulation factor Substances 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 230000002596 correlated effect Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 102000043253 matrix Gla protein Human genes 0.000 claims 1
- 108010057546 matrix Gla protein Proteins 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940039716 prothrombin Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/10—Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Transplantation (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Claims (8)
1. Postupak za procjenu rizika od zatajenja alografta i smrtnosti pacijenata povezane s neuspjehom alografta kod bolesnika nakon transplantacije organa koji uključuje
a) procjenu statusa vitamina K u krvi, plazmi ili serumu izvučenim ili uzetim od navedenog pacijenta nakon transplantacije mjerenjem stupnja karboksilacije cirkulirajućih ekstrahepatičnih Gla-proteina,
b) pružanje referentne sheme koja prikazuje status vitamina K referentne populacije zdravih ljudi u kojoj je stupanj karboksilacije cirkulirajućih ekstrahepatičnih Gla-proteina mjeren na isti način kao u koraku a),
c) uspoređivanje vrijednosti dobivene u koraku a) s referentnom shemom koraka b), pri čemu je vrijednost izvan normalnog raspona navedene referentne sheme indikativna za rizik od neuspjeha alografta i/ili smrtnosti pacijenta.
2. Postupak prema zahtjevu 1, naznačen time što je Gla-protein odabran iz skupine koju čine MGP, protrombin, bilo koji od faktora zgrušavanja VII, IX i X, proteini C, S i Z koji inhibiraju koagulaciju, osteokalcin, matriks-Gla-protein, GRP, Gas6, periostin, faktor sličan periostinu, i bilo koji od četiri transmembranska Gla-proteina.
3. Postupak prema zahtjevu 2, naznačen time što je Gla-protein MGP.
4. Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time što se navedeni stupanj karboksilacije cirkulirajućih ekstrahepatičnih Gla-proteina procjenjuje iz jednog od ukupnog nekarboksiliranog MGP-a (t-ucMGP), fosfo-nekarboksiliranog MGP-a (p-ucMGP), desfosfo-nekarboksiliranog MGP-a (dp-ucMGP), ucOC i ucGRP.
5. Postupak prema bilo kojem od patentnih zahtjeva 1 do 4, naznačen time što je vrijednost dp-ucMGP ispod normalnog raspona navedene referentne sheme indikativna za nizak rizik i vrijednost dp-ucMGP veća od normalnog raspona indikativna je za veći rizik, čiji je opseg koreliran s odstupanjem od normalnog raspona.
6. Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time što je navedena transplantacija organa transplantacija bubrega i navedeni pacijent je pacijent s transplantacijom bubrega.
7. Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time što se navedeni stupanj karboksilacije cirkulirajućih ekstrahepatičnih Gla-proteina procjenjuje na osnovu jednog od cOC, dp-cMGP i cGRP.
8. Postupak prema bilo kojem od patentnih zahtjeva 1 do 7, naznačen time što testovi za nekarboksilirane Gla-proteine daju rastuće vrijednosti kod povećanja insuficijencije vitamina K i testovi za karboksilirane Gla-proteine daju opadajuće vrijednosti kod povećanja insuficijencije vitamina K.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12170756.6A EP2671574A1 (en) | 2012-06-04 | 2012-06-04 | Use of vitamin K to decrease allograft failure and patient mortality after organ transplantation |
| PCT/EP2013/061519 WO2013182579A1 (en) | 2012-06-04 | 2013-06-04 | New biomarkers to estimate the risk of allograft failure and patient mortality after organ transplantation |
| EP13729629.9A EP2856152B1 (en) | 2012-06-04 | 2013-06-04 | New biomarkers to estimate the risk of allograft failure and patient mortality after organ transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211676T1 true HRP20211676T1 (hr) | 2022-02-18 |
Family
ID=48651994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211676TT HRP20211676T1 (hr) | 2012-06-04 | 2013-06-04 | Novi biomarkeri za procjenu rizika neuspjeha alografta i smrtnosti pacijenata nakon transplantacije organa |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150153352A1 (hr) |
| EP (3) | EP2671574A1 (hr) |
| DK (1) | DK2856152T3 (hr) |
| ES (1) | ES2891249T3 (hr) |
| HR (1) | HRP20211676T1 (hr) |
| HU (1) | HUE056601T2 (hr) |
| LT (1) | LT2856152T (hr) |
| PL (1) | PL2856152T3 (hr) |
| PT (1) | PT2856152T (hr) |
| SI (1) | SI2856152T1 (hr) |
| WO (2) | WO2013182578A1 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3258924A2 (en) * | 2015-02-20 | 2017-12-27 | VitaK B.V. | Vitamin k and capillary function |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635478A (en) * | 1989-09-18 | 1997-06-03 | Yale University | Use of calcitonin gene-related peptide to regulate immune response |
| AU5341699A (en) * | 1998-08-06 | 2000-02-28 | University Of Pittsburgh | Antiproliferative naphthoquinones, derivatives, compositions, and uses thereof |
| ES2296634T3 (es) | 1999-07-04 | 2008-05-01 | Cardiovascular Research Institute Of Maastricht (Carim) | Ensayo de diagnostico para proteina gla de matriz humana y su utilizacion como biomarcador. |
| US7700296B2 (en) | 1999-07-04 | 2010-04-20 | Mgp Diagnostics As | Diagnostic assay for human Matrix Gla-protein and its use as a biomarker |
| ES2286070T3 (es) | 2000-05-12 | 2007-12-01 | Nattopharma Asa | Producto alimenticio que contiene vitamina k2. |
| WO2004108748A2 (en) * | 2002-09-24 | 2004-12-16 | Dow, Kenneth, Centocor, Inc. | Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses |
| WO2005054503A2 (en) * | 2003-12-03 | 2005-06-16 | Novartis Ag | Biomarkers for graft rejection |
| WO2005107731A1 (ja) * | 2004-05-12 | 2005-11-17 | Eisai R & D Management Co., Ltd. | ビタミンk2を有効成分として含む治療剤 |
| RU2318500C2 (ru) * | 2005-10-18 | 2008-03-10 | Общество С Ограниченной Ответственностью "Митотехнология" | Способ воздействия на организм путем адресной доставки биологически активных веществ в митохондрии, фармацевтическая композиция для его осуществления и соединение, применяемое для этой цели |
| EP2164500B1 (en) * | 2007-05-25 | 2013-12-04 | Idogen AB | The use of zeburaline for the treatment of autoimmune diseases or immune rejection of transplants |
| US20130178522A1 (en) * | 2010-07-19 | 2013-07-11 | James M. Jamison | Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease |
-
2012
- 2012-06-04 EP EP12170756.6A patent/EP2671574A1/en not_active Withdrawn
-
2013
- 2013-06-04 EP EP13729629.9A patent/EP2856152B1/en active Active
- 2013-06-04 US US14/405,107 patent/US20150153352A1/en not_active Abandoned
- 2013-06-04 DK DK13729629.9T patent/DK2856152T3/da active
- 2013-06-04 PT PT137296299T patent/PT2856152T/pt unknown
- 2013-06-04 HU HUE13729629A patent/HUE056601T2/hu unknown
- 2013-06-04 SI SI201331932T patent/SI2856152T1/sl unknown
- 2013-06-04 WO PCT/EP2013/061518 patent/WO2013182578A1/en active Application Filing
- 2013-06-04 ES ES13729629T patent/ES2891249T3/es active Active
- 2013-06-04 PL PL13729629T patent/PL2856152T3/pl unknown
- 2013-06-04 EP EP13729628.1A patent/EP2854788A1/en active Pending
- 2013-06-04 LT LTEPPCT/EP2013/061519T patent/LT2856152T/lt unknown
- 2013-06-04 WO PCT/EP2013/061519 patent/WO2013182579A1/en active Application Filing
- 2013-06-04 US US14/405,106 patent/US20150141386A1/en not_active Abandoned
- 2013-06-04 HR HRP20211676TT patent/HRP20211676T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL2856152T3 (pl) | 2022-02-07 |
| SI2856152T1 (sl) | 2022-01-31 |
| US20150141386A1 (en) | 2015-05-21 |
| WO2013182579A1 (en) | 2013-12-12 |
| EP2671574A1 (en) | 2013-12-11 |
| ES2891249T3 (es) | 2022-01-26 |
| US20150153352A1 (en) | 2015-06-04 |
| EP2856152B1 (en) | 2021-08-04 |
| DK2856152T3 (da) | 2021-11-01 |
| LT2856152T (lt) | 2021-12-10 |
| WO2013182578A1 (en) | 2013-12-12 |
| EP2856152A1 (en) | 2015-04-08 |
| HUE056601T2 (hu) | 2022-02-28 |
| EP2854788A1 (en) | 2015-04-08 |
| PT2856152T (pt) | 2021-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013006764A2 (pt) | método para avaliar um paciente, kit, meio legível por computador, método para avaliar um tratamento, método para avaliar o risco de um paciente, método para monitorar, método de diagnosticar, sistema de teste, método para classificar ou agrupar uma população de indivíduos, método para avaliar um desfecho substituto, método para tratar, uso de pelo menos um biomarcador, uso de um agente | |
| RU2013138721A (ru) | Способы и наборы для прогнозирования риска дыхательной недостаточности, почечной недостаточности или тромбопении у пациента, страдающего сепсисом, путем измерения уровней эндокана в крови | |
| PH12015500110A1 (en) | Inhibitors of alpha-crystallin aggregation for the treatment of cataract | |
| DK2885641T3 (da) | Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension | |
| EA201700123A1 (ru) | Способ прогнозирования варианта лекарственного препарата для лечения депрессии | |
| WO2015034886A3 (en) | Wellness panel for companion animals | |
| BR102012002812A8 (pt) | método para determinar a influência de uma variável em um fenômeno | |
| BR112015014232A2 (pt) | lesão renal aguda | |
| WO2012122374A3 (en) | Non-invasive methods for diagnosing chronic organ transplant rejection | |
| HRP20211676T1 (hr) | Novi biomarkeri za procjenu rizika neuspjeha alografta i smrtnosti pacijenata nakon transplantacije organa | |
| BR112015016027A2 (pt) | método para prever o tempo de parto (ttd), método para determinar o risco de parto prematuro, método para determinar o risco de uma mulher grávida romper espontaneamente a membrana corioaminiótica e kit | |
| BR112014005720A2 (pt) | método de seleção e/ou identificação de um antagonista de usp1, antagonista de uaf1 e/ou um antagonista de id que promove uma alteração no destino celular do dito método | |
| ES2475492B1 (es) | Composición para su utilización como plasma de control anormal de la coagulación en ensayos in vitro | |
| BR112012024175A2 (pt) | hbf e a1m como marcadores de estágio precoce para preeclampsia | |
| BR112015017432A2 (pt) | métodos para o tratamento de indicações cardiovasculares | |
| RU2014113841A (ru) | Способ ранней диагностики эндогенной интоксикации | |
| BR112013032238A2 (pt) | método para a determinação de uma variação do volume plasmático e dispositivos para implementar o método | |
| ES2521841B1 (es) | Procedimiento de diagnóstico y pronóstico de la enfermedad renal crónica en un sujeto humano | |
| CY1121406T1 (el) | Διαγνωση καρδιακης ανεπαρκειας | |
| RU2012144141A (ru) | Способ оценки вероятности возникновенения переломов при остеопорозе у женщин | |
| Hugli | Letter by Hugli regarding article,“Diagnosis of acute aortic dissection by D-dimer: the International Registry of Acute Aortic Dissection Substudy on Biomarkers (IRAD-Bio) experience” | |
| RU2014110649A (ru) | Способ диагностики развития стенозирования стентов | |
| UA79063U (ru) | Способ интегрированной диагностики возможности рецидивов алкогольной зависимости | |
| UA99186U (uk) | Спосіб ранньої діагностики ризику мікрогемореологічних порушень при хронічному обструктивному захворюванні легень, поєднаному з ішемічною хворобою серця | |
| UA96483U (uk) | Спосіб діагностики можливого перебігу туберкульозу легенів |